GHK-Cu

Peptide

GHK-Cu (Copper peptide GHK-Cu) is a naturally occurring tripeptide containing glycine, histidine, lysine, and a copper ion. It was first identified in human plasma and has been extensively studied for wound healing, tissue regeneration, and anti-aging applications. Research suggests it may stimulate collagen synthesis, promote wound healing, and exhibit anti-inflammatory properties.

Quick Answer

What it is

GHK-Cu (Copper peptide GHK-Cu) is a naturally occurring tripeptide containing glycine, histidine, lysine, and a copper ion. It was first identified in human plasma and has been extensively studied for wound healing, tissue regeneration, and anti-aging applications.

Key findings

  • Grade B: Wound Healing Rate (Skin Health)
  • Grade B: Collagen Synthesis (Skin Health)
  • Grade C: Liver Protection

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: GHK-Cu

Quick Facts: GHK-Cu

  • Best Evidence:Grade B
  • Conditions Studied:2
  • Research Outcomes:15
  • Grade B Findings:2
  • Key Effect:Skin Health
A0
B2
C10
D3
2 conditions · 15 outcomes

Detailed Outcomes

|
B
Wound Healing Rate
Moderate Increase
moderate↑Improves
B
Collagen Synthesis
Moderate Increase
moderate↑Improves
C
Skin Thickness
Small Increase
small↑Improves
C
Liver Protection
8 preclinical studies support this finding. Primarily preclinical evidence.
moderate↑Improves
C
Safety/Tolerability
4 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Pulmonary Function
4 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Anti-Cancer Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
D
Lipid Profile
2 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
D
Angiogenesis
2 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Hair Growth
Small Increase
small↑Improves

Research Citations (49)

Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration.
(2026)
PMID: 41371501
An injectable hydroxyapatite microsphere filler loaded with GHK-Cu tripeptide for anti-Inflammatory and antioxidant.
(2025)
PMID: 40716276
Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing.
(2025)
PMID: 39902373
Nanoengineered Self-Assembling Peptides with Increased Proteolytic Stability Promote Wound Healing.
(2025)
PMID: 39937124
Copper Complexes with New Glycyl-l-histidyl-l-lysine-Hyaluronan Conjugates Show Antioxidant Properties and Osteogenic and Angiogenic Synergistic Effects.
(2025)
PMID: 40123442
Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?
(2025)
PMID: 39795193
Rigid-flexible nanocarriers loaded with active peptides for antioxidant and anti-inflammatory applications in skin.
(2024)
PMID: 38394858
The glycyl-l-histidyl-l-lysine-Cu(2+) tripeptide complex attenuates lung inflammation and fibrosis in silicosis by targeting peroxiredoxin 6.
(2024)
PMID: 38879894
Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application.
(2024)
PMID: 38026438
Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide.
(2024)
PMID: 40766919

Related Peptides

Tyrothricin

Peptide

1 shared condition · 6 outcomes

Tyrothricin is a cyclic peptide antibiotic complex from Bacillus brevis - the first peptide antibiotic used in humans (1939). Contains 60-80% tyrocidine (cyclic decapeptides) and 20-40% gramicidin (linear peptides). Over 60 years of clinical use with no significant resistance reported. RCT (DoriPha, n=321): Tyrothricin lozenges showed 64% improved complete remission vs placebo at 72 hours for acute pharyngitis. Used topically for sore throat, skin infections. SAFETY CONCERN: Systemic toxicity limits to topical/local use only.

TB-500

Peptide

1 shared condition · 23 outcomes

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino acid peptide present in most human cells. It has been investigated for its potential role in tissue repair, wound healing, and regeneration. Research, primarily in animal models, suggests it may promote angiogenesis, cell migration, and reduce inflammation. Human clinical trials are limited.

Sermorelin

Peptide

1 shared condition · 18 outcomes

Sermorelin (GHRH 1-29) is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH) that retains full biological activity. It was FDA-approved in 1990 for diagnostic use and in 1997 for treating childhood growth hormone deficiency. Sermorelin stimulates natural GH release from the pituitary gland through the hypothalamic-pituitary axis, producing physiological GH patterns with built-in safety through somatostatin feedback regulation.